Fig. 1From: Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapyDose distributions of (a) SPArc and (b) RO-IMPT plans, and the corresponding DVHs (solid line for SPArc, dashed line for RO-IMPT) comparisons for patient 6Back to article page